Candriam S.C.A. Madrigal Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$171.37 - $283.23 $1.54 Million - $2.55 Million	-9,000 Reduced 33.33%	18,000 $4.81 Million
Q4 2023 Feb 14, 2024	SELL	$120.4 - $237.13 $240,800 - $474,260	-2,000 Reduced 6.9%	27,000 $6.25 Million
Q2 2023 Aug 08, 2023	BUY	$203.88 - $312.0 $5.91 Million - $9.05 Million	29,000 New	29,000 $6.7 Million
Q2 2021 Jul 20, 2021	SELL	$97.2 - $137.59 $3.08 Million - $4.36 Million	-31,722 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$110.06 - $133.7 $6.92 Million - $8.4 Million	-62,862 Reduced 66.46%	31,722 $3.53 Million
Q3 2020 Oct 19, 2020	SELL	$99.78 - $124.21 $798,240 - $993,680	-8,000 Reduced 7.8%	94,584 $11.2 Million
Q2 2020 Jul 23, 2020	BUY	$60.13 - $125.71 $3.71 Million - $7.75 Million	61,634 Added 150.51%	102,584 $11.6 Million
Q4 2019 Jan 21, 2020	SELL	$84.28 - $118.5 $42,140 - $59,250	-500 Reduced 1.21%	40,950 $4,000
Q1 2019 May 02, 2019	BUY	$103.48 - $143.84 $1.03 Million - $1.44 Million	10,000 Added 31.8%	41,450 $5.19 Million
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $1.66 Million - $3.77 Million	17,500 Added 125.45%	31,450 $3.55 Million
Q3 2018 Nov 07, 2018	BUY	$207.3 - $300.31 $943,215 - $1.37 Million	4,550 Added 48.4%	13,950 $2.99 Million
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $954,570 - $2.95 Million	9,400 New	9,400 $2.63 Million

295

21.9M

819K

644K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.58B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.